Grantham, Mayo, Van Otterloo & Co (GMO)
KNSA icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-38,900
Closed -$596K – 848
2020
Q3 		$596K Buy
+38,900
New +$730K ﹤0.01% 603

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s KNSA Position: Q4 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2020, closing a stake of 38,900 shares — an estimated $596K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in KNSA in Q3 2020 and held it in 1 quarter. The position peaked at $596K in Q3 2020. 108 funds tracked by Wall St. Rank hold KNSA as of Q4 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Kiniksa Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 38,900 Kiniksa Pharmaceuticals shares in Q4 2020, an estimated $596K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Kiniksa Pharmaceuticals position peaked at $596K in Q3 2020.
  • 108 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q4 2020, filed 12 Feb 2021.